{"id":"sumatriptan-succinate-oral-tablet","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Chest pain or pressure"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Drowsiness"},{"rate":"5-10","effect":"Tingling or numbness"},{"rate":"5-10","effect":"Flushing"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Warm sensation"}]},"_chembl":{"chemblId":"CHEMBL1201150","moleculeType":"Small molecule","molecularWeight":"413.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sumatriptan is a selective serotonin 5-HT1B/1D receptor agonist that works through two primary mechanisms: it causes constriction of dilated cranial blood vessels implicated in migraine pathophysiology, and it inhibits the release of vasoactive neuropeptides from trigeminal nerve terminals. This dual action rapidly terminates the migraine attack and associated symptoms including pain, nausea, and photosensitivity.","oneSentence":"Sumatriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals, causing vasoconstriction and inhibiting neuropeptide release to relieve migraine headaches.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:08.877Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults"}]},"trialDetails":[{"nctId":"NCT03229798","phase":"PHASE1","title":"Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2018-01-17","conditions":"Migraine Disorders","enrollment":19},{"nctId":"NCT04257851","phase":"PHASE4","title":"Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache","status":"COMPLETED","sponsor":"Damanhour Teaching Hospital","startDate":"2020-02-15","conditions":"Post-Dural Puncture Headache","enrollment":60},{"nctId":"NCT01381796","phase":"PHASE1","title":"Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2009-12","conditions":"Compare Bioequivalence Patches Previously Used in the NP101-007 Study","enrollment":63},{"nctId":"NCT00546650","phase":"PHASE1","title":"Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2007-11","conditions":"Healthy","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sumigran tablets"],"phase":"marketed","status":"active","brandName":"Sumatriptan Succinate Oral Tablet","genericName":"Sumatriptan Succinate Oral Tablet","companyName":"Damanhour Teaching Hospital","companyId":"damanhour-teaching-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sumatriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals, causing vasoconstriction and inhibiting neuropeptide release to relieve migraine headaches. Used for Acute treatment of migraine with or without aura in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}